ArcherDX combines superior targeted NGS technology with cGMP manufacturing and medical device quality standards to become the premium partner to help you develop, validate and commercialize in vitro diagnostic (IVD) tests such as companion diagnostic (CDx) tests.
From conception to post-launch support, Archer will be your long-term partner in IVD development.
ArcherDX distributes Archer® products worldwide to ensure global customer access.
Entrectinib - Archer is co-developing an IVD with Ignyta, Inc. to identify and enroll patients into the Phase-2 STARTRK-2 clinical trial for entrectinib, a tyrosine kinase inhibitor targeting NTRK1/2/3, ROS1 and ALK in solid tumors.
CC-122 - Archer is co-developing an IVD with Celgene to detect a proprietary gene signature to identify DLBCL patients that are most likely to respond to CC-122, a cereblon-modulating agent under investigation in multiple disease settings.
Read more about these partnershipsSee the Archer CDx pipeline
2477 55th Street, Suite 202
Boulder, CO 80301